VivoSeq
Other

Microvascular Dysfunction

0

Pipeline Programs↗

3

Active Trials↗

0

Companies Involved↗

Microvascular Dysfunction is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting2 · 29%
Withdrawn1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
Recruiting·—·Phase 1·NCT05946798·40 enrolled
Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI
Recruiting·National Medical Research Center for Cardiology, Ministry of Health of Russian Federation·N/A·NCT06376630·300 enrolled
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
Not yet recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06787430·170 enrolled
Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction
Completed·—·Phase 4·NCT02525081·63 enrolled
Comprehensive Treatment of Angina in Women With Microvascular Dysfunction
Completed·—·N/A·NCT02910154·62 enrolled
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Completed·MMayo Clinic·Phase 2·NCT00586820·23 enrolled
Targeting Microvascular Dysfunction in Young Hypertensive Patients
Withdrawn·QQueen's University, Belfast·Phase 4·NCT01047423

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)